1. Scrip
  2. >>Business
  3. >>Deals

Novartis Blows Storm Clouds Off Sandoz US In Aurobindo Sale

 
• By Kevin Grogan

Novartis's proposed sale of its generic oral solids portfolio – which has been battered by US price erosion – and the Sandoz US dermatology business to Aurobindo Pharma, in a deal potentially worth $1bn, allows the unit to finally concentrate on biosimilars, value-added medicines and complex generics.

Dark clouds
Gloom lifting over Sandoz • Source: Shutterstock

Novartis AG has acted pretty swiftly to lift the gloom that was hanging over its Sandoz International GMBH unit which should have a brighter future following the sale of the latter's troubled generic oral solids portfolio and US dermatology business to India's Aurobindo Pharma Ltd..

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business